Location History:
- Belmont, MA (US) (2014)
- Arlington, MA (US) (2018)
Company Filing History:
2 out of 63 
1 out of 850 
Years Active: 2014-2018
Title: Kenneth Egnard Lind: Innovator in Cancer Treatment
Introduction
Kenneth Egnard Lind is a notable inventor based in Arlington, MA, who has made significant contributions to the field of cancer treatment. With a total of two patents to his name, Lind's work focuses on innovative methods that aim to improve therapeutic outcomes for cancer patients.
Latest Patents
Lind's latest patents include groundbreaking inventions related to pyridinonyl PDK1 inhibitors. The first patent outlines methods of treatment using these inhibitors, which are designed to target and treat cancer effectively. The second patent further elaborates on the same inhibitors and their application in cancer treatment, showcasing Lind's commitment to advancing medical science.
Career Highlights
Throughout his career, Kenneth Egnard Lind has worked with prominent companies in the pharmaceutical industry. He has been associated with Sunesis Pharmaceuticals, Inc. and Millennium Pharmaceuticals Limited, where he has contributed to the development of innovative cancer therapies.
Collaborations
Lind has collaborated with several talented individuals in his field, including Kathy Jingyuan Cao and Edward Yin-Shiang Lin. These collaborations have likely enriched his research and contributed to the success of his inventions.
Conclusion
Kenneth Egnard Lind's work in developing pyridinonyl PDK1 inhibitors represents a significant advancement in cancer treatment. His contributions to the pharmaceutical industry and collaborations with other professionals highlight his dedication to improving patient outcomes.